AMRX Insider Trading Activity and SEC Form 4 Filings
Trump's trades in AMRX
From his financial disclosures
$15K+
1 purchase
$15K+
1 sale
Sale
Mar 30, 2026
Reported 45d later
$15K - $50K
Purchase
Mar 4, 2026
Reported 71d later
$15K - $50K
Many orders in these accounts are placed by the account manager.
AMRX insider trading summary
Over the past 12 months, insiders at Amneal Pharmaceuticals, Inc. (AMRX) reported 7 sales worth $9.8M by 5 insiders and no open-market purchases on SEC Form 4. Net insider selling was $9.8M.
Latest AMRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 13, 2026 | John Kiely | Director | Sell | $882K (50,000 @ $17.64) |
| Aug 12, 2026 | Jason B. Daly | EVP, Chief Legal Officer | Sell | $3.7M (210,000 @ $17.40) |
| Aug 12, 2026 | Nikita Shah | Executive Vice President | Sell | $2.6M (146,403 @ $17.51) |
| Aug 11, 2026 | Jason B. Daly | EVP, Chief Legal Officer | Sell | $117K (6,613 @ $17.70) |
| May 11, 2026 | Deborah M. Autor | Director | Sell | $451K (34,819 @ $12.94) |
| Nov 17, 2025 | Ted C Nark | Director | Sell | $586K (50,000 @ $11.72) |
| Nov 12, 2025 | Nikita Shah | Executive Vice President | Sell | $1.6M (131,856 @ $11.92) |
| Aug 27, 2025 | John Kiely | Director | Sell | $295K (32,000 @ $9.23) |
| Aug 25, 2025 | Nikita Shah | Executive Vice President | Sell | $60K (6,340 @ $9.50) |
| Aug 22, 2025 | Nikita Shah | Executive Vice President | Sell | $1.1M (114,492 @ $9.66) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.